A putative therapeutic target in frontotemporal dementia: Q13148

Ablatotech Signals reports today on a putative therapeutic target — Q13148 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in frontotemporal dementia.

Background

The protein associated with UniProt accession Q13148 is being explored as a putative target that warrants experimental validation in the context of frontotemporal dementia (FTD). Frontotemporal dementia is a group of neurodegenerative disorders characterized by progressive changes in personality, behavior, and language, resulting from the degeneration of the frontal and temporal lobes of the brain. Investigating the role of Q13148 in FTD could provide valuable insights into the underlying mechanisms of the disease and potential therapeutic strategies.

Data-mining rationale

The rationale for focusing on Q13148 stems from a comprehensive analysis that cross-referenced reviewed human entries in UniProt related to frontotemporal dementia against 27 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The presence of Q13148 in expression-profiling studies suggests a potential involvement in the pathophysiology of FTD. However, it is noteworthy that no Phase 1 or higher clinical programs have been identified for this candidate, indicating a significant gap in its exploration for therapeutic development.

Why prior analyses may have missed this

Prior analyses may have overlooked the significance of Q13148 due to the limitations of the GEO datasets, many of which predate the implementation of modern empirical-Bayes statistical methods, such as the limma package. These methods are essential for accurate multiple-testing corrections and may have led to an underestimation of the relevance of Q13148 in previous studies. A re-analysis of these datasets using updated statistical methodologies could yield more reliable insights into the expression patterns of Q13148 and its potential implications in frontotemporal dementia.

Reasoning for further validation

To substantiate the role of Q13148 in frontotemporal dementia, several experimental approaches are recommended: 1. Re-analyze the matched GEO datasets using the limma package, applying a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes, including Q13148, through quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. Investigate the tissue specificity of Q13148 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its relevance in the affected brain regions. 4. Utilize STRING and OmniPath databases to explore the pathway context of Q13148, examining its interactions and potential biological roles in the disease. 5. If validation is achieved, evaluate the druggability of Q13148 through databases like DGIdb and ChEMBL to assess its potential as a therapeutic target.

References